Rosenfeld PJ, Brown DM, Heier JS, MARINA Study Group et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355(14):1419–31

Article  CAS  PubMed  Google Scholar 

Brown DM, Michels M, Kaiser PK et al (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116(1):57-65.e5

Article  PubMed  Google Scholar 

Boyer DS, Heier JS, Brown DM et al (2009) A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 116(9):1731–1739

Article  PubMed  Google Scholar 

Bhisitkul RB, Mendes TS, Rofagha S et al (2015) Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study. Am J Ophthalmol 159(5):915–24.e2

Article  PubMed  Google Scholar 

Singer MA, Awh CC, Sadda S et al (2012) HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 119(6):1175–1183

Article  PubMed  Google Scholar 

Gupta B, Adewoyin T, Patel SK, Sivaprasad S (2011) Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration. Br J Ophthalmol 95(3):386–390

Article  PubMed  Google Scholar 

Lalwani GA, Rosenfeld PJ, Fung AE et al (2009) A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 148(1):43-58.e1

Article  CAS  PubMed  Google Scholar 

Fung AE, Lalwani GA, Rosenfeld PJ et al (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143(4):566–583

Article  CAS  PubMed  Google Scholar 

Schmidt-Erfurth U, Eldem B, Guymer R, EXCITE Study Group et al (2011) EXCITE Study Group Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 118(5):831–9 (dosage reduction)

Article  PubMed  Google Scholar 

Bilgic A, Kodjikian L, Mathis T et al (2021) Single injection response to anti-vascular endothelial growth factor agents in patients with wet age related macular degeneration: incidence and characteristics. Retina 41(9):1901–1910

Article  CAS  PubMed  Google Scholar 

Dugel PU, Singh RP, Koh A et al (2020) HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 128(1):89–99

Article  PubMed  Google Scholar 

Baumal CR, Bodaghi B, Singer M et al (2020) Expert opinion on management of intraocular inflammation, retinal vasculitis, and/or vascular occlusion after brolucizumab treatment. Ophthalmol Retina S2468–6530(20):30400

Google Scholar 

Monés J, Srivastava SK, Jaffe GJ et al (2020) Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology S0161–6420(20):31075–31077

Google Scholar 

https://www.brolucizumab.info. Information on brolucizumab related adverse events. Accessed 15 September 2023

Bilgic A, Kodjikian L, March de Ribot F et al (2021) Real-world experience with brolucizumab in wet age-related macular degeneration: the REBA study. J Clin Med 10(13):2758

Article  CAS  PubMed  PubMed Central  Google Scholar 

Spaide RF, Jaffe GJ, Sarraf D et al (2020) Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group. Ophthalmology 127(5):616–636

Article  PubMed  Google Scholar 

Ehlken C, Jungmann S, Böhringer D et al (2014) Switch of anti-VEGF agents is an option for non-responders in the treatment of AMD. Eye 28(5):538–545

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bilgic A, Kodjikian L, Srivastava S et al (2021) Initial pro re nata brolucizumab for exudative AMD: the PROBE study. J Clin Med 10(18):4153

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chakraborty D, Maiti A, Sengupta S, Mondal S, Nandi K, Chakraborty S (2022) Initial experience in treating polypoidal choroidal vasculopathy with brolucizumab in Indian eyes - a multicenter retrospective study. Indian J Ophthalmol 70(4):1295–1299

Article  PubMed  PubMed Central  Google Scholar 

Baumal CR, Spaide RF, Vajzovic L et al (2020) Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology 127(10):1345–1359

Article  PubMed  Google Scholar 

Puxeddu I, Caltran E, Rocchi V et al (2016) Hypersensitivity reactions during treatment with biological agents. Clin Exp Rheumatol 34(1):129–132

PubMed  Google Scholar 

Kabanarou SA, Xirou T, Mangouritsas G et al (2017) Full-thickness macular hole formation following anti-VEGF injections for neovascular age-related macular degeneration. Clin Interv Aging 12:911–915

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miura M, Iwasaki T, Goto H (2011) Macular hole formation after intravitreal bevacizumab administration in a patient with myopic choroidal neovascularization. Retin Cases Brief Rep 5(2):149–5220

Article  PubMed  Google Scholar 

Sally DR, Loewenstein A, Arnold JJ, Yang YC, Gedif K, Best C, Patel H, Tadayoni R, Heier JS (2023) Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies. Eye (Lond). 37(6):1242–1248

Article  Google Scholar 

Yu JS, Carlton R, Agashivala N, Hassan T, Wykoff CC (2021) Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis. J Manag Care Spec Pharm 27(6):743–752

PubMed  Google Scholar 

Sharma A, Kumar N, Parachuri N, Sadda SR, Corradetti G, Heier J, Chin AT, Boyer D, Dayani P, Arepalli S, Kaiser P (2021) Brolucizumab-early real-world experience: BREW study. Eye (Lond) 35(4):1045-1047. Epub 2020 Jul 24. Erratum in: Eye (Lond). 2020 Dec 15. https://doi.org/10.1038/s41433-020-1111-x